DENV-2
Overview
DENV-2 is one of the four dengue virus serotypes and is historically associated with the highest rates of severe dengue in secondary infections, particularly the DENV1→DENV2 sequence. The 1981 Santiago de Cuba DENV-2 epidemic was the first large DHF/DSS outbreak in the Americas and marks Cuba’s entry into the modern dengue epidemiology literature. DENV-2 has two major genotypic lineages (Asian and American) with measurably different virulence and transmissibility characteristics. It serves as the chimeric backbone for the DENVax (TAK-003) vaccine.
Key Points from Literature
- The Asian genotype of DENV-2 replicates to higher titres in human dendritic cells, infects Ae. aegypti more efficiently, and is transmitted at higher rates than American DENV-2 strains. Amino acid changes in NS proteins appear to underlie these differences in epidemic potential (see Guzman2016 - Dengue Infection). Bhatt2020 specifically implicates differences in the NS3 protein and replication complex efficiency as the molecular basis for the genotypic virulence difference; the Asian genotype also replicates more efficiently in Ae. aegypti salivary glands — the anatomical step required for transmission to humans (see Bhatt2020 - Dengue Pathogenesis Review).
- The Santiago de Cuba 1997 DENV-2 epidemic is a pivotal natural experiment: susceptible individuals (no prior dengue) developed predominantly subclinical infections; individuals with prior DENV-1 infection almost invariably developed overt disease (overt:subclinical ratio ≈ 1). The epidemic also revealed rapid within-epidemic selection: month-to-month increases in severe disease proportion and case fatality rate were observed, accompanied by a stable amino acid switch in NS1 — suggesting viral evolution during an epidemic can shift virulence (see Guzman2016 - Dengue Infection).
- The second Cuban DENV-2 epidemic in 1981 was the first large DHF/DSS outbreak in the Americas, establishing Cuba as a key setting for dengue pathogenesis research.
- DENV-2 serves as the attenuated PDK-53 backbone for the DENVax chimeric tetravalent vaccine candidate (TAK-003); the prM and E genes of wild-type DENV-1, -3, and -4 are substituted into the PDK-53 scaffold (see Dengue Vaccine Candidates).
- The Cuban cohort studies (Garcia2009, Garcia2010) were conducted in individuals who had DENV-1 (1977) as their original sensitising infection and DENV-2 (1981) as a likely secondary infection before DENV-4 (2006).
CNS Tropism and Neuropathogenesis
DENV-2, along with DENV-3, is specifically implicated in direct CNS invasion causing encephalitis (rather than mere encephalopathy from systemic effects). This CNS tropism is one of three pathways to neurological disease in dengue — the others being metabolic/systemic encephalopathy and autoimmunity-mediated complications such as ADEM (see Dengue Neurological Complications). The molecular basis likely resides in NS protein variation, as genetic changes affecting NS proteins are associated with altered tissue tropism and epidemic potential across serotypes (see Shih2023 - Autoimmune Disease Risk After Dengue, Guzman2016 - Dengue Infection).
Anti-Platelet IgM in DENV-2 Infection
Lin2001 - IgM Anti-Platelet Autoantibody in Dengue Patients tested a single DENV-2 dengue fever patient (acute serum, August 1996) and found anti-platelet IgM levels comparable to DENV-3 DF acute patients (26.0±4.2% reactive platelets; MFI 132.5±18.5 vs. normal: 5.2±1.6%, MFI 46.2±7.2). This confirms that the anti-platelet IgM phenomenon is not DENV-3-specific, consistent with all four dengue serotypes sharing the NS1-P1 (aa 1–15) B-cell epitope (Huang et al. 1999, cited in Lin2001).
Contradictions & Debates
- Asian genotype DENV-2 is described as more virulent than American DENV-2 — but the comparative assessment of genotype virulence is complicated by confounding factors: host immunity, mosquito vector competence, and epidemiological context (density of susceptible individuals). A direct genotypic virulence effect independent of these factors has not been cleanly demonstrated in humans.
Related Pages
- DENV-1
- DENV-3
- DENV-4
- Antibody-Dependent Enhancement
- NS1 Protein
- CYD-TDV
- Dengue Vaccine Candidates
- Latin America
- Dengue Neurological Complications
Sources
- Guzman2016 - Dengue Infection
- Shih2023 - Autoimmune Disease Risk After Dengue (CNS invasion neuropathogenesis pathway)
- Lin2001 - IgM Anti-Platelet Autoantibody in Dengue Patients (DENV-2 patient confirmed anti-platelet IgM; comparable to DENV-3 levels — cross-serotype generalisation)
- Oishi2003 - PAIgG and Thrombocytopenia in Secondary Dengue (DENV-2 antigen used in HI titer panel; secondary-infection PAIgG mechanism context)
- Palacios2016 - Autoimmunity in Dengue Literature Review (Wan2012 cross-serotype autoantibody data: similar autoantibody levels in DENV-2/3/4)
- Vo2020 - Autoantibody Profiling in Dengue (Cambodia 2012–2013; DENV-2 present in 18.18% ASD and 12.5% DHF; minority serotype)
- Dejnirattisai2010 - Anti-prM Antibodies Enhance Dengue ADE (anti-prM hmAbs from DENV-infected donors fully cross-reactive against DENV-2 antigen; consistent with complete serotype cross-reactivity of the anti-prM response)
- Pang2017 - DHF Pathogenesis Review (DENV-2 SE Asian genotype > American genotype virulence in humans and mosquitoes; intra-serotype evolution; all four serotypes in ADE context; review, China)
- Bhatt2020 - Dengue Pathogenesis Review (Asian genotype DENV-2: NS3 protein differences + efficient Ae. aegypti salivary gland replication underlie higher virulence than American genotype; DENV-2 secondary infection produces highest viraemia across infection sequences; review, India)
- Cheng2015 - NS1 P311-330 Anti-PDI Autoantibodies in DHF (DENV-2 in 1/15 DHF patients in Vietnamese paediatric cohort; anti-endothelial autoantibody study)
- Farias2024 - Dengue Mimickers (all four serotypes noted as co-circulating in Brazil 2024 epidemic with >6M cases; background epidemiology; Brazil narrative review — secondary source)
- Hung2008 - Anti-Platelet Anti-Endothelial Autoantibodies Vietnam (DENV-2 co-circulating with DENV-3/4 in HCMC Vietnam 1998–2002 cohort; serotype-confirmed by virus isolation/RT-PCR)
- Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review (DENV-2 and DENV-4 cited as higher-virulence serotypes citing Martina 2009; all four serotypes referenced in coagulation factor mimicry and autoantibody context; Kolkata India review — secondary source)